Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst
1. Akeso's ivonescimab shows significant OS benefit for NSCLC patients. 2. Final analysis of HARMONi study confirms ivonescimab's efficacy. 3. Analysts project ivonescimab could rival Keytruda in market. 4. SMMT's price forecast raised due to increased approval probability. 5. Potential acquisition target status for SMMT emphasized by analysts.